6550--MPLS - Toxicology Drugs of Abuse Supplies Reagents, Calibrators, and Controls for Assays - Solicitation
ID: 36C26325Q0057Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNETWORK CONTRACT OFFICE 23 (36C263)Saint Paul, MN, 55101, USA

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/2108ec44d6ab45738105a3b70d6ca090/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the acquisition of FDA-approved CEDIA and DRI drugs of abuse reagents, calibrators, and controls specifically for assays related to Oxycodone, Ecstasy, Heroin (6MAM), and Hydrocodone. This procurement is a Brand Name Only requirement, exclusively for products manufactured by Microgenics Corporation, to ensure compliance with stringent health standards and operational efficiency at the Minneapolis VA Medical Center, which serves as the sole national provider of drug testing for VA hospitals. The total award amount is capped at $1,000,000, with a contract duration from December 8, 2024, to September 30, 2025, and options for extensions through September 30, 2029. Interested vendors should direct inquiries to Contract Specialist Alisha L Milander at Alisha.Milander@va.gov, with proposals due by November 21, 2024.

    Point(s) of Contact
    Alisha MilanderContract Specialist
    701-239-3700 x3176
    Alisha.Milander@va.gov
    Files
    Title
    Posted
    36C26325Q0057_1.docx
    The presolicitation notice outlines a contract opportunity with the Minneapolis VA Medical Center for the procurement of FDA-approved drugs of abuse reagents, calibrators, and controls specifically for Oxycodone, Ecstasy, Heroin (6MAM), and Hydrocodone assays from Microgenics Corporation. The solicitation number is 36C26325Q0057, and submissions are due by November 18, 2024, at 1:00 PM Central Time. The opportunity is set aside as a Brand Name Only solicitation, indicating that only specified brand products will be considered. The point of contact for this solicitation is Contract Specialist Alisha Milander, available via email at Alisha.Milander@va.gov or by phone at 701-239-3700 x3176. This procurement aligns with federal regulations regarding drug testing and substance abuse monitoring in healthcare settings, particularly for veterans receiving care at the Minneapolis facility.
    36C26325Q0057.docx
    The document outlines a solicitation from the Department of Veterans Affairs for the acquisition of FDA-approved CEDIA and DRI drugs of abuse reagents, calibrators, and controls specifically for assays related to Oxycodone, Ecstasy, Heroin, and Hydrocodone. With a requisition number 36C26325Q0057, the solicitation is due on November 21, 2024, and emphasizes a brand-name-only requirement for products manufactured by Microgenics Corporation. The contract spans from December 8, 2024, to September 30, 2025, with extension options available through September 30, 2029. The total award amount is limited to $1,000,000, and the solicitation encourages submissions from small businesses. It specifies the delivery point at the Minneapolis VA Medical Center, where various product quantities need to be shipped. Additionally, detailed instructions to offerors are included, specifying the importance of adhering to solicitation documentation and submission processes. Successful bidders must be compliant with federal procurement regulations, ensuring the integrity of the contracting process. This request reflects a commitment to maintaining high-quality standards in supplying critical health products for the veteran population.
    P03 - Brand Name Only Justification - Redacted.docx
    The Department of Veterans Affairs is initiating a procurement for FDA-approved CEDIA and DRI Drugs of Abuse reagents, calibrators, and controls specifically for Oxycodone, Ecstasy, Heroin (6MAM), and Hydrocodone assays required by the Toxicology Laboratory of the Minneapolis VA Medical Center (MPLS VAMC). Utilizing FAR 13.5 Simplified Procedures, the procurement will be a Brand Name Only justification with a procurement plan for a firm-fixed price contract covering a base year plus four option years. The MPLS VAMC, being the sole national provider of drug testing for VA hospitals, necessitates these specific reagents manufactured exclusively by Microgenics Corporation to meet stringent health standards without triggering labor-intensive validation processes that would hinder operational capabilities. The anticipated costs are determined to be fair and reasonable based on prior contracts and market research, which demonstrated that competing vendors cannot provide equivalent supplies due to regulatory certifications. Future acquisitions may consider greater market competition opportunities, but current circumstances necessitate this sole source procurement to maintain compliance and operational integrity in federal drug testing programs.
    Similar Opportunities
    761-25-1-014-0011 -Chelmsford CMOP MED SURGE TEST STRIPS -(VA-25- 00014793)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is soliciting quotes for the procurement of One Touch Verio glucose test strips under solicitation RFQ: 36C77025Q0037, specifically reserved for Service-Disabled Veteran-Owned Small Businesses (SDVOSB). This procurement aims to ensure the acquisition of new Original Equipment Manufacturer (OEM) medical supplies, prohibiting gray market items and requiring verification of OEM authorization from vendors. The test strips are critical for patient care, as they are prescribed and must adhere strictly to physician orders, with no substitutions allowed. Interested vendors must submit their responses by November 22, 2024, including a signed SF1449 cover page, an Excel spreadsheet quote, and proof of OEM authorization, while ensuring compliance with federal procurement regulations. For further inquiries, vendors can contact Jennifer L Knight at jennifer.knight@va.gov or call 913-684-0162.
    6505--Metformin SA Tablets REPACK PROGRAM
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Metformin HCL SA Tablets, aimed at ensuring a consistent supply for various governmental entities, including the VA, Department of Defense, Bureau of Prisons, and others. The procurement will cover a one-year contract with the possibility of four additional one-year extensions, requiring offerors to provide a unique National Drug Code (NDC) number and distinct labeling for the supplied products. This initiative is critical for maintaining the availability of essential pharmaceuticals, with estimated annual requirements detailed for two groups: Other Government Agencies and the VA Repack Program. The solicitation, numbered 36E79725R0003, is scheduled for electronic release on December 3, 2024, with a closing date of December 17, 2024. Interested parties can direct inquiries to Teresa Hussain at teresa.hussain@va.gov or by phone at 708-786-5852, and are encouraged to monitor SAM.gov for updates.
    The Navy Medical Readiness Logistics Command Detachment Fort Detrick has a requirement for the Drug Demand Reduction Program, for the initial (screen) immunoassay for the detection of 6-Acetylmorphine Immunoassay Reagent Kits in urine > 10 ng/mL.
    Active
    Dept Of Defense
    The Department of Defense, specifically the Navy Medical Readiness Logistics Command Detachment Fort Detrick, is seeking proposals for the procurement of FDA-approved Immunoassay Reagent Kits designed for the detection of 6-acetylmorphine (6AM) in urine samples. The contract requires vendors to provide reagent kits compatible with Beckman Coulter AU5800 series analyzers, capable of conducting up to 500,000 tests per month over a five-year period, while adhering to stringent FDA and quality management documentation standards. This procurement is critical for the Drug Demand Reduction Program, ensuring accurate and reliable drug testing within the Department of Defense. Interested vendors must submit technical documentation by October 25, 2024, with final quotes due by November 22, 2024. For further inquiries, contact James Berghaier at 215-697-2022 or via email at james.berghaier@navy.mil.
    6630--V16 Lab Chemistry and Immunochemistry CPRR BPA (VA-25-00010416)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Quotation (RFQ) for a Blanket Purchase Agreement (BPA) focused on Chemistry and Immunochemistry instrumentation and testing for the South Central VA Health Care Network (VISN 16). This procurement aims to standardize automated equipment across 8 medical center and 20 outpatient laboratories, ensuring compliance with the 1988 Clinical Laboratory Improvement Act and FDA approval for all reagents, while also providing operator training and 24/7 repair services. The initiative underscores the VA's commitment to enhancing laboratory capabilities through modern technology, with site visits permitted until February 28, 2025, allowing vendors to assess laboratory conditions and align their offerings with specific site requirements. Interested contractors can contact Diyonne Williams, the Contracting Officer, at Diyonne.Williams@va.gov for further information.
    6509--Warfarin Tablets (VA-25-00012328)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) 36E79725R0007 for the procurement of Warfarin Tablets, aimed at ensuring a reliable supply for various federal health agencies, including the Department of Defense and the Bureau of Prisons. This unrestricted procurement will cover multiple tablet strengths and packaging sizes, with an estimated annual usage detailed across 16 product types, and will be awarded for an initial one-year period with options for four additional years. The successful contractor must provide unique labeling and a National Drug Code (NDC) associated with their product, emphasizing the importance of compliance with federal regulations in pharmaceutical supply. Interested vendors should note that the solicitation will be electronically issued around November 13, 2024, with a response deadline of November 27, 2024; inquiries can be directed to Contract Specialist Adrienne Albachiara at adrienne.albachiara@va.gov.
    MED SURGE - OMNIPODS for Multiple CMOPS 760, 761, and 766A
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting quotes for the procurement of Omnipod 5 G6 Reservoirs for its Consolidated Mail Outpatient Pharmacy (CMOP) facilities located in Leavenworth, Chelmsford, and Ladson. The procurement aims to secure a total of 10,800 units, with specific delivery schedules set for early January 2025, ensuring timely access to essential medical supplies for veteran healthcare services. This acquisition is critical for maintaining the reliability of medical supply chains within the VA system, particularly given the specialized nature of the products and the sole source justification for this procurement. Interested vendors must submit their quotes by November 25, 2024, and ensure compliance with all outlined requirements, including the Buy American Act and FDA guidelines. For further inquiries, contact Jennifer L Knight at jennifer.knight@va.gov or call 913-684-0162.
    6640--VA Central California Health Care System Chemistry & Immunoassay CPRR Equipment and Tests
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified contractors to provide clinical laboratory analyzer equipment for Chemistry and Immunoassay testing on a Cost Per Reportable Result (CPRR) basis for the VA Central California Health Care System. This procurement involves a five-year Indefinite Delivery, Indefinite Quantity (IDIQ) contract, which will span from April 2025 to September 2029, and includes specific ordering periods for various laboratory tests and equipment. The initiative is crucial for enhancing diagnostic capabilities and ensuring high-quality healthcare services for veterans, with a focus on automation, reliability, and compliance with federal regulations. Interested parties can contact Contract Specialist Tawnya S Krommenhoek at tawnya.krommenhoek@va.gov or David J. Alvarez at david.alvarez4@va.gov for further details regarding the solicitation, identified as 36C26125Q0065.
    6550--Tuberculosis testing reagents
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking vendors to provide tuberculosis testing reagents through a Blanket Purchase Agreement (BPA) aimed at enhancing healthcare services for veterans. The procurement includes FDA-approved testing solutions, specifically QIAGEN medical equipment such as the LIAISON QuantiFERON TB Gold Plus and related items, which must meet defined specifications to ensure reliability and safety in testing. This initiative is critical for improving patient care and will span a base year with four optional years, allowing for flexible ordering across various VA facilities in California and Arizona. Interested parties should direct inquiries to Carlos Magana at carlos.magana@va.gov, with proposals due by November 27, 2024, at 9:00 AM Pacific Time.
    6505--Verapamil Hydrochloride (HCL) Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) National Acquisition Center is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0006 to procure Verapamil Hydrochloride (HCL) Tablets. This procurement aims to ensure an uninterrupted supply of the drug for various federal entities, including the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will have a duration of one year, with the potential for four additional one-year options, and the estimated annual requirements include specific dosages and quantities of the tablets. Interested vendors must submit their proposals by December 4, 2024, and are encouraged to check SAM.gov for updates regarding the solicitation. For inquiries, vendors can contact Contract Specialist Deborah Fassl at Deborah.Fassl@va.gov or by phone at 708-786-5894.
    6505--Abiraterone Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0005 to procure Abiraterone Acetate Tablets, an essential medication for various federal health care programs. The procurement aims to secure a reliable supply of 250mg Abiraterone Acetate Tablets, with an estimated annual requirement of 71,997 bottles, to support the VA, Department of Defense, Bureau of Prisons, and other federal entities. This contract will span one base year with four optional one-year extensions, ensuring continuity of supply for critical health services. Interested offerors should monitor sam.gov for the electronic issuance of the solicitation on or about November 22, 2024, with a closing date of December 6, 2024; inquiries can be directed to Richard Mahario at Richard.Mahario@va.gov or by phone at 708-786-5247.